CoChat

Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial

Open access
Rosenstock, Julio, Buse, John B., Azeem, Rehan, Prabhakar, Prakash, Kjems, Lise, Huang, Holly, Baron, Michelle A. · 2018 · Diabetes Care
Cited by 53

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: ITCA 650 (exenatide in osmotic mini-pump) continuously delivers exenatide subcutaneously for 3–6 months. Two doses of ITCA 650 were compared with placebo in patients with uncontrolled type 2 diabetes. RESEARCH DESIGN AND METHODS: This 39-week, phase 3, double-blind, placebo-controlled trial randomized 460 patients aged 18–80 years with glycated hemoglobin (HbA1c) 7.5–10% [58–86 mmol/mol] 1:1:1 to placebo, ITCA 650 40 μg/day, or ITCA 650 60 μg/day. Primary end point was change in HbA1c at 39 weeks. RESULTS: Least squares (LS) mean change from baseline HbA1c was −1.1% [−12.2 mmol/mol] and −1.2% [−13.2 mmol/mol] for ITCA 650 40 and 60 μg/day, respectively (P < 0.001 vs. placebo −0.1% [−1.3 mmol/mol]). In a prespecified analysis, greater HbA1c reductions occurred in patients not receiving sulfonylureas (SUs) versus those receiving SUs (−1.7% vs. −1.2% [−18.6 and −13.1 mmol/mol]). At week 39, HbA1c <7% [53 mmol/mol] was attained in 37%, 44%, and 9% of ITCA 650 40 μg/day, ITCA 650 60 μg/day, and placebo groups, respectively (P < 0.001 each dose vs. placebo). LS mean change from baseline body weight was −2.3 kg and −3.0 kg for ITCA 650 40 and 60 μg/day, respectively (P ≤ 0.015 vs. placebo −1.0 kg). Nausea was the most common adverse event (AE) and subsided over time. Discontinuation for gastrointestinal AEs occurred in 7.2% with ITCA and 1.3% with placebo. Most AEs associated with procedures to place and remove ITCA 650 were mild and transient. CONCLUSIONS: ITCA 650 significantly reduced HbA1c and weight compared with placebo and was well tolerated in patients with uncontrolled type 2 diabetes on oral antidiabetes medications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc17-1306

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 15

  1. Breitscheidel, 2010, Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper, J Med Econ, 13, 8, 10.3111/13696990903479199 · DOI · Paper page
  2. Palmer, 2016, Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis, JAMA, 316, 313, 10.1001/jama.2016.9400 · DOI · Paper page
  3. Yu, 2016, Liraglutide versus exenatide once weekly: persistence, adherence, and early discontinuation, Clin Ther, 38, 149, 10.1016/j.clinthera.2015.11.017 · DOI
  4. Rohloff, 2008, DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months, J Diabetes Sci Technol, 2, 461, 10.1177/193229680800200316 · DOI
  5. Henry, 2013, A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes, Clin Ther, 35, 634, 10.1016/j.clinthera.2013.03.011 · DOI
  6. Henry, 2013, Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes [published correction appears in Diabetes Care 2013;36:2559–2565], Diabetes Care, 36, 2559, 10.2337/dc12-2410 · DOI · Paper page
  7. Henry, 2014, Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes, J Diabetes Complications, 28, 393, 10.1016/j.jdiacomp.2013.12.009 · DOI · Paper page
  8. Kayaniyil, 2016, A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus, Diabetes Ther, 7, 27, 10.1007/s13300-016-0155-1 · DOI · Paper page
  9. Kim, 2007, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes, Diabetes Care, 30, 1487, 10.2337/dc06-2375 · DOI · Paper page
  10. Htike, 2017, Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis, Diabetes Obes Metab, 19, 524, 10.1111/dom.12849 · DOI · Paper page
  11. Calvert, 2007, Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study, Br J Gen Pract, 57, 455
  12. Khunti, 2013, Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people, Diabetes Care, 36, 3411, 10.2337/dc13-0331 · DOI · Paper page
  13. Abdul-Ghani, 2015, Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial, Diabetes Obes Metab, 17, 268, 10.1111/dom.12417 · DOI · Paper page
  14. Rosenstock, 2015, Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin, Diabetes Care, 38, 376, 10.2337/dc14-1142 · DOI · Paper page
  15. Henry, 2016, Efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes: an uncontrolled open-label extension of the DURATION-1 study, Diabetes Technol Ther, 18, 677, 10.1089/dia.2016.0107 · DOI · Paper page

Cited by

See all 53

Metadata

Authors
Rosenstock, J., Buse, J. B., Azeem, R., Prabhakar, P., Kjems, L., Huang, H., & Baron, M. A.
Venue
Diabetes Care
Published
2017-12-14
Volume
41
Issue
2
Pages
333-340
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2774301756
Cited by
53
References
9
FWCI
4.27
Type
journal article
Language
en
Open access
green
Funders
Intarcia Therapeutics, Inc.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.